Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

被引：0
|
作者：
Waidmann, O. [1 ]
Abou-Alfa, G. K. [2 ]
Meyer, T. [3 ]
Cheng, A-L [4 ]
El-Khoueiry, A. B. [5 ]
Rimassa, L. [6 ]
Ryoo, B-Y [7 ]
Cicin, I [8 ]
Merle, P. [9 ]
Chen, Y. H. [10 ]
Park, J-W [11 ]
Blanc, J-F [12 ]
Bolondi, L. [13 ]
Klumpen, H-J [14 ]
Chan, S. L. [15 ]
Dadduzio, V [16 ]
Hessel, C. [17 ]
Borgman-Hagey, A. E. [17 ]
Schwab, G. [17 ]
Kelley, R. K. [18 ]
机构：
[1] Univ Liver & Canc Ctr Frankfurt, Frankfurt, Germany
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Royal Free Hosp, London, England
[4] Natl Taiwan Univ Hosp, Taipei, Taiwan
[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Rozzano, Italy
[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[8] Trakya Univ, Sch Med, Edirne, Turkey
[9] Groupement Hosp Lyon Nord, Lyon, France
[10] Liou Ying ChiMei Hosp, Dept Med Oncol, Tainan, Taiwan
[11] Natl Canc Ctr, Goyang, South Korea
[12] CHU, Hop Haut Leveque, Bordeaux, France
[13] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[14] Univ Amsterdam, Dept Med Oncol, Acad Med Ctr, Amsterdam, Netherlands
[15] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China
[16] UOC, Ist Oncol Veneto, IRCCS, Padua, Italy
[17] Exelixis Inc, San Francisco, CA USA
[18] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V763
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [1] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Chen, Yen-Hsun
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.
    Abou-Alfa, Ghassan K.
    Meyer, Tim
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Rimassa, Lorenza
    Ryoo, Baek-Yeol
    Cicin, Irfan
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Bolondi, Luigi
    Klumpen, Heinz Josef
    Chan, Stephen Lam
    Dadduzio, Vincenzo
    Hessel, Colin
    Borgman-Hagey, Anne E.
    Schwab, Gisela
    Kelley, Robin Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [3] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen Lam
    Lim, Ho Yeong
    Baron, Ari David
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas Cheung
    Lougheed, Julie
    Milwee, Steven
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Parnis, F.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 283
  • [5] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).
    Rimassa, Lorenza
    Cicin, Irfan
    Blanc, Jean-Frederic
    Klumpen, Heinz Josef
    Zagonel, Vittorina
    Tran, Albert
    Kim, Stefano Chong Hun
    Lin, Zhong-Zhe
    Tam, Vincent C.
    Hazra, Saswati
    Mangeshkar, Milan
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Kelley, Robin Kate
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Rimassa, L.
    Cicin, I
    Blanc, J-F
    Kluempen, H-J
    Zagonel, V
    Tran, A.
    Kim, S.
    Lin, Z-Z
    Tam, V. C.
    Hazra, S.
    Mangeshkar, M.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 283
  • [7] Outcomes in patients who had received sorafenib as the only prior systemic therapy in the Phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
    Strasser, S. I.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 21 - 22
  • [8] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Blanc, J. F.
    Meyer, T.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Cicin, I.
    Chen, Y.
    Bolondi, L.
    Dadduzio, V.
    Baron, A.
    Lin, Z-Z.
    Adriani, J.
    Kelly, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 237 - 237
  • [10] Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
    Llovet, J.
    Ricci, S.
    Mazzaferro, V.
    Hilgard, P.
    Raoul, J.
    Zeuzem, S.
    Poulin-Costello, M.
    Moscovici, M.
    Voliotis, D.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345